NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $99.19 -2.40 (-2.36%) (As of 09/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$99.07▼$102.1350-Day Range$92.37▼$102.4352-Week Range$63.80▼$103.52Volume9.97 million shsAverage Volume9.75 million shsMarket Capitalization$7.56 billionAssets Under Management$7.60 billionDividend Yield0.02%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… #1 Pre-IPO Opportunity For 2024 [Take Action Now!] (Ad)According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starlink, Elon Musk’s giant internet company worth over $180 billion.Click here now for the urgent details. SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.51%0.52%Other Expenses0.00%0.33%0.49%0.58%0.54%Total Expense0.35%0.71%0.70%0.73%0.71%Fee Waiver0.00%-0.45%-0.52%-0.68%-0.58%Net Expense0.35%0.61%0.61%0.58%0.59% XBI ETF News HeadlinesBiotech Boom Ahead? Key Stocks and ETFs to Watch Now (XBI)The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital.September 23 at 11:11 AM | marketbeat.comSPDR S&P Biotech ETF (NYSEARCA:XBI) Sets New 1-Year High at $103.52September 19, 2024 | americanbankingnews.com320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are already moving their money… and preparing for even stranger days ahead. Over 320 hedge funds have quietly sold THIS famous stock – to prepare for a dramatic market shiftSeptember 23, 2024 | Chaikin Analytics (Ad)Halozyme cut to Neutral at J.P. Morgan on valuationSeptember 19, 2024 | msn.comSPDR S&P Regional Banking ETF (KRE): How to BuySeptember 16, 2024 | fool.comXBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)September 16, 2024 | seekingalpha.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $89.29 at the beginning of 2024. Since then, XBI stock has increased by 11.1% and is now trading at $99.19. View the best growth stocks for 2024 here. Who are SPDR S&P Biotech ETF's major shareholders? Top institutional shareholders of SPDR S&P Biotech ETF include Healthcare of Ontario Pension Plan Trust Fund (4.06%), Avoro Capital Advisors LLC (3.98%), Logos Global Management LP and Logos Global Management LP. How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS) and Micron Technology (MU). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings143 Fund Statistics Assets Under Management$7.60 billion Average Daily Volume$7.02 million Discount/Premium0.04% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume55,977 Put Options21,569 Call Options34,408 Short Interest55,500,000 shs Miscellaneous Outstanding Shares76,220,000Beta1.11 Creation Unit50,000 Creation Fee$250.00 Top 10 XBI HoldingsExact Sciences (NASDAQ:EXAS)Holding Weight: 3.61%Gilead Sciences (NASDAQ:GILD)Holding Weight: 3.24%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.08%AbbVie (NYSE:ABBV)Holding Weight: 3.06%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.90%Amgen (NASDAQ:AMGN)Holding Weight: 2.85%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 2.84%Natera (NASDAQ:NTRA)Holding Weight: 2.72%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 2.63%Sarepta Therapeutics (NASDAQ:SRPT)Holding Weight: 2.56%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 9/23/2024 by MarketBeat.com Staff From Our PartnersElection Shocker: Trump Won't See This ComingIf you suspect Democrats will play dirty games in this election… You are RIGHT! Executive Order 14019 ha...Banyan Hill Publishing | SponsoredInvesting Legend Warns: “Disturbing Event Is Coming to America”America Repeats Act That's Destroyed Stock Markets For 200 Years The Fed has now repeated a mistake that ce...Stansberry Research | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding SPDR S&P Biotech ETF You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.